AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 82 min read$TLRY

Tilray Brands posts record Q1 revenue $257.1M and gross profit $77.5M; adjusted EBITDA reaffirmed

Tilray Brands reported Q1 2027 revenue of $257.1M, up 23% YoY, and gross profit of $77.5M with a 30% margin. The company had a net loss of $40.0M but reaffirmed adjusted EBITDA guidance of $68M-$75M. Beverage and international segments showed growth, while cannabis margins improved.

Original reporting
tradingview.com
Published Oct 8, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray Brands posts record Q1 revenue $257.1M and gross profit $77.5M; adjusted EBITDA reaffirmed — source image
Source · tradingview.com
Decision brief

The 30-second read

$TLRYBearishMed
01

Why it matters

Earnings beat revenue expectations, margins improved, but loss persists; guidance unchanged.

02

Market read

Tilray's earnings may lift sentiment in the cannabis sector and influence peer valuations.

03

What to watch

Integration of BrewDog acquisition and debt repayment effects are not fully reflected in the earnings.

Relevance 9/10Novelty 9/10Timing: today

Background

Tilray Brands reported Q1 FY2027 record revenue of $257.1M, gross profit $77.5M, net loss $40M, and reaffirmed FY2027 adjusted EBITDA guidance of $68-75M.

Company-level read

Ticker impact

$TLRYBearishMedium confidence
Context

Tilray Brands reported record Q1 FY2027 revenue of $257.1M and reaffirmed FY2027 adjusted EBITDA guidance of $68-75M.

Expected impact

likely modest upside as investors price in revenue growth and stable guidance

Evidence & confidence

Revenue growth and improved margins suggest operational progress, but ongoing loss limits bullishness.

Market effects

Sector

Positive earnings could boost broader cannabis sector sentiment.

Regional

North American cannabis market may see increased investor interest.

Global

International investors may view Tilray's expansion as a sign of sector maturation.

Counterpoint

What could challenge this read

Continued net loss and debt reduction may indicate underlying cost pressures despite revenue growth.

Key entities

  • company
    Tilray Brands

    Cannabis producer

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

3 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min